Mcintyre Freedman & Flynn Investment Advisers Inc Bristol Myers Squibb CO Transaction History
Mcintyre Freedman & Flynn Investment Advisers Inc
- $167 Billion
- Q3 2025
A detailed history of Mcintyre Freedman & Flynn Investment Advisers Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mcintyre Freedman & Flynn Investment Advisers Inc holds 8,000 shares of BMY stock, worth $374,480. This represents 0.22% of its overall portfolio holdings.
Number of Shares
8,000
Previous 6,000
33.33%
Holding current value
$374,480
Previous $278 Million
29.91%
% of portfolio
0.22%
Previous 0.2%
Shares
10 transactions
Others Institutions Holding BMY
# of Institutions
2,679Shares Held
1.58BCall Options Held
28.2MPut Options Held
28.4M-
Vanguard Group Inc Valley Forge, PA196MShares$9.17 Billion0.14% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.43 Billion0.15% of portfolio
-
State Street Corp Boston, MA96.6MShares$4.52 Billion0.16% of portfolio
-
Jpmorgan Chase & CO New York, NY86.2MShares$4.03 Billion0.26% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA73MShares$3.42 Billion0.55% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $99.5B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...